Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.

Kenta YagiMarin MitstuiYoshito ZamamiTakahiro NiimuraYuki Izawa-IshizawaMitsuhiro GodaMasayuki ChumaKimiko FukunagaTakahiro ShibataShunsuke IshidaTakumi SakuradaNaoto OkadaHirofumi HamanoYuya HorinouchiYasumasa IkedaHiroaki YanagawaKeisuke Ishizawa

Published in: Cancer medicine (2020)

PPIs prevent hypertension in bevacizumab-treated patients but may reduce bevacizumab's anti-tumoral effects by inducing VEGF expression.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
blood pressure
chronic kidney disease
peritoneal dialysis
prognostic factors
endothelial cells